Responses
Regular and young investigator award abstracts
Clinical trials completed
298 Final analysis of the phase 1 trial of NY-ESO-1–specific T-cell receptor (TCR) T-cell therapy (letetresgene autoleucel; GSK3377794) in patients with advanced synovial sarcoma (SS)
Compose a Response to This Article
Other responses
No responses have been published for this article.
